Press Enter to search · ESC to close

Crypto

Zai Lab Reports Positive First-in-Human Data for ZL-1503 in Atopic Dermatitis

Zai Lab announced positive preliminary first-in-human results from the single-ascending-dose portion of the global Phase 1/1b study of ZL-1503, its self-developed long-acting IL-13/IL-31 receptor alpha bispecific antibody. The results are to be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting. The company said the data may support reduced dosing intervals.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback